Central Hypothyroidism: Investigations and Management
Diagnostic Approach
Central hypothyroidism requires measurement of both TSH and free T4 simultaneously, as TSH alone will miss the diagnosis—the hallmark is low or inappropriately normal TSH with low free T4. 1, 2, 3
Initial Laboratory Investigations
Measure TSH and free T4 together as the first-line tests; central hypothyroidism presents with low free T4 alongside low-to-normal (or even slightly elevated) TSH levels, distinguishing it from primary hypothyroidism where TSH is markedly elevated 1, 2, 3
Obtain early morning (8 AM) cortisol and ACTH levels before initiating levothyroxine therapy, as central hypothyroidism frequently coexists with adrenal insufficiency, and starting thyroid hormone without corticosteroid coverage can precipitate life-threatening adrenal crisis 4, 5, 6
Measure additional pituitary hormones including prolactin, IGF-1, LH, FSH, testosterone (in men), and estradiol (in women) to identify other pituitary deficiencies, since central hypothyroidism is rarely isolated 4, 2
Check basic metabolic panel for hyponatremia and hyperkalemia patterns that suggest concurrent adrenal insufficiency 4, 6
Imaging Studies
Obtain MRI of the sella with pituitary cuts to evaluate for pituitary enlargement, stalk thickening, suprasellar convexity, or mass lesions that may explain the central hypothyroidism 4
MRI abnormalities such as pituitary enlargement, heterogeneous enhancement, and increased gland height are present in most patients with hypophysitis at diagnosis 4
Common Diagnostic Pitfalls
Never rely on TSH alone for screening—a TSH-reflex strategy (measuring only TSH, then adding free T4 if abnormal) will systematically miss central hypothyroidism because TSH may be normal or only slightly low 1, 7
Recognize that TSH may be inappropriately "normal" (within reference range) despite low free T4 due to secretion of biologically inactive TSH molecules 1, 2, 8
Distinguish central hypothyroidism from non-thyroidal illness syndrome, where acute illness causes low free T4 with normal TSH; clinical context and timing relative to acute illness are critical 1, 2
Be aware that positive predictive value of low free T4 for central hypothyroidism is only 2-4% in current practice due to increased thyroid testing rates and medications that lower free T4 7
Management Strategy
Always initiate glucocorticoid replacement at least one week before starting levothyroxine in patients with confirmed or suspected adrenal insufficiency, as thyroid hormone accelerates cortisol metabolism and can trigger adrenal crisis. 4, 5, 6
Treatment Initiation
Start hydrocortisone 20 mg in the morning and 10 mg in the afternoon for at least 7 days before levothyroxine if adrenal insufficiency is present or suspected 4, 5
Begin levothyroxine at full replacement dose (approximately 1.6 mcg/kg/day) in patients <70 years without cardiac disease once adrenal function is secured 5
Use lower starting doses (25-50 mcg/day) in patients >70 years or with cardiac disease, titrating gradually by 12.5-25 mcg every 6-8 weeks 5
Monitoring and Dose Adjustment
Target free T4 levels in the mid-to-upper normal range rather than TSH, as TSH cannot be used to guide therapy in central hypothyroidism 2, 3
Recheck free T4 every 6-8 weeks during dose titration until stable, then every 6-12 months long-term 5
Do not use TSH levels to assess adequacy of replacement—TSH may remain low or normal despite adequate free T4 levels 1, 2, 3
Special Monitoring for Immune Checkpoint Inhibitor-Induced Central Hypothyroidism
Measure TSH and free T4 every 4-6 weeks for the first 6 months of pembrolizumab or similar agents, then every 3 months thereafter 6
Check early morning ACTH and cortisol monthly for 6 months, then every 3 months for 6 months, then every 6 months for 1 year to detect delayed-onset hypophysitis 4, 6
Continue immunotherapy in most cases, as thyroid dysfunction rarely requires treatment interruption once hormone replacement is established 4, 5, 6
Critical Safety Considerations
Never start levothyroxine before ruling out adrenal insufficiency in any patient with suspected central hypothyroidism or hypophysitis—this is the single most important safety principle 4, 5, 6
Educate patients to report unexplained fatigue, weakness, orthostatic symptoms, or nausea as these may herald adrenal crisis 6
Provide medical alert identification and stress-dose steroid education to all patients with confirmed adrenal insufficiency 6
Long-Term Management
Monitor for resolution of pituitary enlargement on follow-up MRI after 2 months in hypophysitis cases, as most resolve spontaneously 4
Recognize that central hypothyroidism is usually permanent after hypophysitis, requiring lifelong levothyroxine replacement in >90% of cases 4
Screen for development of other autoimmune endocrinopathies in patients with immune checkpoint inhibitor-induced disease 4, 6
The incidence of newly diagnosed central hypothyroidism is approximately 2 cases per 100,000 population per year, making it a rare condition that requires high clinical suspicion and appropriate testing strategies to detect 7. The key to successful management lies in recognizing the disorder early, securing adrenal function before thyroid replacement, and using free T4 rather than TSH to guide therapy 1, 2, 3.